{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T00:33:15Z","timestamp":1793665995374,"version":"4.5.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T00:00:00Z","timestamp":1692835200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T00:00:00Z","timestamp":1692835200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Santen SA"},{"name":"Aerie Pharmaceuticals Ireland Ltd"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose\u00a0\u00a0\u00a0<\/jats:title>\n                    <jats:p>\n                      To compare the efficacy and safety of the fixed-dose combination (FDC) of netarsudil 0.02%\/latanoprost 0.005% ophthalmic solution (NET\/LAT; Roclanda\n                      <jats:sup>\u00ae<\/jats:sup>\n                      ) with bimatoprost 0.03%\/timolol maleate 0.5% (BIM\/TIM; Ganfort\n                      <jats:sup>\u00ae<\/jats:sup>\n                      ) ophthalmic solution in the treatment of open-angle glaucoma (OAG) and ocular hypertension (OHT).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>MERCURY-3 was a 6-month prospective, double\u2013masked, randomized, multicenter, active-controlled, parallel-group, non-inferiority study. Patients (\u2265\u200918\u00a0years) with a diagnosis of OAG or OHT in both eyes that was insufficiently controlled with topical medication (IOP\u2009\u2265\u200917\u00a0mmHg in\u2009\u2265\u20091 eye and\u2009&lt;\u200928\u00a0mmHg in both eyes) were included. Following washout, patients were randomized to once-daily NET\/LAT or BIM\/TIM for up to 6\u00a0months; efficacy was assessed at Week 2, Week 4, and Month 3; safety was evaluated for 6\u00a0months. Comparison of NET\/LAT relative to BIM\/TIM for mean IOP at 08:00, 10:00, and 16:00\u00a0h was assessed at Week 2, Week 6, and Month 3. Non-inferiority of NET\/LAT to BIM\/TIM was defined as a difference of\u2009\u2264\u20091.5\u00a0mmHg at all nine time points through Month 3 and\u2009\u2264\u20091.0\u00a0mmHg at five or more of nine time points through Month 3.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Overall, 430 patients were randomized (NET\/LAT,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009218; BIM\/TIM,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009212), and all received at least one dose of study medication. Efficacy analyses were performed at Month 3 on 388 patients (NET\/LAT,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009184; BIM\/TIM,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009204). NET\/LAT demonstrated non-inferiority to BIM\/TIM, with a between-treatment difference in IOP of\u2009\u2264\u20091.5\u00a0mmHg achieved at all time points and\u2009\u2264\u20091.0\u00a0mmHg at the majority of time points (six of nine) through Month 3. Mean diurnal IOP during the study ranged from 15.4 to 15.6\u00a0mmHg and 15.2 to 15.6\u00a0mmHg in the NET\/LAT and BIM\/TIM groups respectively, with no between-group statistically significant difference. No significant differences were observed in key secondary endpoints. No serious, treatment-related adverse events (AEs) were observed, and AEs were typically mild\/moderate in severity. The most common treatment-related AEs were conjunctival hyperemia (NET\/LAT, 30.7%; BIM\/TIM, 9.0%) and cornea verticillata (NET\/LAT, 11.0%; BIM\/TIM, 0%).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Once-daily NET\/LAT was non-inferior to BIM\/TIM in IOP reduction in OAG and OHT, with AEs consistent with previous findings. NET\/LAT offers a compelling alternative FDC treatment option for OAG and OHT.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00417-023-06192-0","type":"journal-article","created":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T05:02:43Z","timestamp":1692853363000},"page":"179-190","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["MERCURY-3: a randomized comparison of netarsudil\/latanoprost and bimatoprost\/timolol in open-angle glaucoma and ocular hypertension"],"prefix":"10.1007","volume":"262","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7507-4512","authenticated-orcid":false,"given":"Ingeborg","family":"Stalmans","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kin Sheng","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Oddone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marek","family":"Fichtl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose I.","family":"Belda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anton","family":"Hommer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guna","family":"Laganovska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9dric","family":"Schweitzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bogomil","family":"Voykov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomasz","family":"Zarnowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0904-4849","authenticated-orcid":false,"given":"G\u00e1bor","family":"Holl\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,24]]},"reference":[{"key":"6192_CR1","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1001\/archopht.120.6.701","volume":"120","author":"MA Kass","year":"2002","unstructured":"Kass MA, Heuer DK, Higginbotham EJ et al (2002) The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 120:701\u2013713. https:\/\/doi.org\/10.1001\/archopht.120.6.701","journal-title":"Arch Ophthalmol"},{"key":"6192_CR2","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1001\/archopht.120.10.1268","volume":"120","author":"A Heijl","year":"2002","unstructured":"Heijl A, Leske MC, Bengtsson B et al (2002) Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol 120:1268\u20131279. https:\/\/doi.org\/10.1001\/archopht.120.10.1268","journal-title":"Arch Ophthalmol"},{"key":"6192_CR3","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1001\/archopht.126.8.1030","volume":"126","author":"BC Chauhan","year":"2008","unstructured":"Chauhan BC, Mikelberg FS, Balaszi AG et al (2008) Canadian Glaucoma Study: 2. risk factors for the progression of open-angle glaucoma. Arch Ophthalmol 126:1030\u20131036. https:\/\/doi.org\/10.1001\/archopht.126.8.1030","journal-title":"Arch Ophthalmol"},{"key":"6192_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/bjophthalmol-2021-egsguidelines","volume":"105","author":"European Glaucoma Society","year":"2021","unstructured":"European Glaucoma Society (2021) European Glaucoma Society Terminology and Guidelines for Glaucoma, 5th Edition. Br J Ophthalmol 105:1\u2013169","journal-title":"Br J Ophthalmol"},{"key":"6192_CR5","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1089\/jop.2017.0138","volume":"34","author":"A Kazemi","year":"2018","unstructured":"Kazemi A, McLaren JW, Kopczynski CC et al (2018) The Effects of Netarsudil Ophthalmic Solution on Aqueous Humor Dynamics in a Randomized Study in Humans. J Ocul Pharmacol Ther 34:380\u2013386. https:\/\/doi.org\/10.1089\/jop.2017.0138","journal-title":"J Ocul Pharmacol Ther"},{"key":"6192_CR6","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/s0002-9394(98)00436-x","volume":"127","author":"CB Toris","year":"1999","unstructured":"Toris CB, Yablonski ME, Wang YL, Camras CB (1999) Aqueous humor dynamics in the aging human eye. Am J Ophthalmol 127:407\u2013412. https:\/\/doi.org\/10.1016\/s0002-9394(98)00436-x","journal-title":"Am J Ophthalmol"},{"key":"6192_CR7","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/sj.tpj.6500181","volume":"3","author":"NC McLaren","year":"2003","unstructured":"McLaren NC, Moroi SE (2003) Clinical implications of pharmacogenetics for glaucoma therapeutics. Pharmacogenomics J 3:197\u2013201. https:\/\/doi.org\/10.1038\/sj.tpj.6500181","journal-title":"Pharmacogenomics J"},{"key":"6192_CR8","doi-asserted-by":"publisher","first-page":"18169","DOI":"10.1038\/s41598-021-97746-x","volume":"11","author":"JH Park","year":"2021","unstructured":"Park JH, Chung HW, Yoon EG et al (2021) Morphological changes in the trabecular meshwork and Schlemm\u2019s canal after treatment with topical intraocular pressure-lowering agents. Sci Rep 11:18169. https:\/\/doi.org\/10.1038\/s41598-021-97746-x","journal-title":"Sci Rep"},{"key":"6192_CR9","doi-asserted-by":"publisher","unstructured":"Shiroma LO, Costa VP (2015) Parasympathomimetics. In: Glaucoma (second edition) Shaarawy TM, Sherwood MB, Hitchings RA, Crowston JG (eds) Elsevier pp 577\u2013582. https:\/\/doi.org\/10.1016\/B978-0-7020-5193-7.00056-X","DOI":"10.1016\/B978-0-7020-5193-7.00056-X"},{"key":"6192_CR10","doi-asserted-by":"publisher","unstructured":"Holl\u00f3 G, Topouzis F, Fechtner RD (2014) Fixed-combination intraocular pressure-lowering therapy for glaucoma and ocular hypertension: advantages in clinical practice. Expert Opin Pharmacother 15:1737\u20131747. https:\/\/doi.org\/10.1517\/14656566.2014.936850","DOI":"10.1517\/14656566.2014.936850"},{"key":"6192_CR11","doi-asserted-by":"publisher","unstructured":"Holl\u00f3 G, Vuorinen J, Tuominen J et al (2014) Fixed-dose combination of tafluprost and timolol in the treatment of open-angle glaucoma and ocular hypertension: comparison with other fixed-combination products. Adv Ther 31:932\u2013944. https:\/\/doi.org\/10.1007\/s12325-014-0151-7","DOI":"10.1007\/s12325-014-0151-7"},{"key":"6192_CR12","doi-asserted-by":"publisher","first-page":"343","DOI":"10.2165\/00044011-200424060-00004","volume":"24","author":"P Denis","year":"2004","unstructured":"Denis P, Lafuma A, Berdeaux G (2004) Medical outcomes of glaucoma therapy from a nationwide representative survey. Clin Drug Investig 24:343\u2013352. https:\/\/doi.org\/10.2165\/00044011-200424060-00004","journal-title":"Clin Drug Investig"},{"key":"6192_CR13","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1007\/s00417-019-04283-5","volume":"257","author":"N Moura-Coelho","year":"2019","unstructured":"Moura-Coelho N, Tavares Ferreira J et al (2019) Rho kinase inhibitors-a review on the physiology and clinical use in Ophthalmology. Graefes Arch Clin Exp Ophthalmol 257:1101\u20131117. https:\/\/doi.org\/10.1007\/s00417-019-04283-5","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"6192_CR14","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.3892\/ijo.2013.2100","volume":"43","author":"J Wang","year":"2013","unstructured":"Wang J, Liu X, Zhong Y (2013) Rho\/Rho-associated kinase pathway in glaucoma (Review). Int J Oncol 43:1357\u20131367. https:\/\/doi.org\/10.3892\/ijo.2013.2100","journal-title":"Int J Oncol"},{"issue":"10","key":"6192_CR15","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1080\/13543776.2019.1670812","volume":"29","author":"E Berrino","year":"2019","unstructured":"Berrino E, Supuran CT (2019) Rho-kinase inhibitors in the management of glaucoma. Expert Opin Ther Pat 29(10):817\u2013827. https:\/\/doi.org\/10.1080\/13543776.2019.1670812","journal-title":"Expert Opin Ther Pat"},{"key":"6192_CR16","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1007\/s40265-019-01130-z","volume":"79","author":"EM Schehlein","year":"2019","unstructured":"Schehlein EM, Robin AL (2019) Rho-Associated Kinase Inhibitors: Evolving Strategies in Glaucoma Treatment. Drugs 79:1031\u20131036. https:\/\/doi.org\/10.1007\/s40265-019-01130-z","journal-title":"Drugs"},{"key":"6192_CR17","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.ajo.2021.01.019","volume":"226","author":"AJ Sit","year":"2021","unstructured":"Sit AJ, Gupta D, Kazemi A et al (2021) Netarsudil Improves Trabecular Outflow Facility in Patients with Primary Open Angle Glaucoma or Ocular Hypertension: A Phase 2 Study. Am J Ophthalmol 226:262\u2013269. https:\/\/doi.org\/10.1016\/j.ajo.2021.01.019","journal-title":"Am J Ophthalmol"},{"key":"6192_CR18","doi-asserted-by":"publisher","first-page":"3001","DOI":"10.1007\/s00417-022-05609-6","volume":"260","author":"H Xu","year":"2022","unstructured":"Xu H, Thomas MT, Lee D et al (2022) Response to netarsudil in goniotomy-treated eyes and goniotomy-naive eyes: a pilot study. Graefes Arch Clin Exp Ophthalmol 260:3001\u20133007. https:\/\/doi.org\/10.1007\/s00417-022-05609-6","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"6192_CR19","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1080\/03007995.2021.1901222","volume":"37","author":"F Zaman","year":"2021","unstructured":"Zaman F, Gieser SC, Schwartz GF et al (2021) A multicenter, open-label study of netarsudil for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension in a real-world setting. Curr Med Res Opin 37:1011\u20131020. https:\/\/doi.org\/10.1080\/03007995.2021.1901222","journal-title":"Curr Med Res Opin"},{"key":"6192_CR20","doi-asserted-by":"publisher","first-page":"6197","DOI":"10.1167\/iovs.16-20189","volume":"57","author":"R Ren","year":"2019","unstructured":"Ren R, Li G, Le TD et al (2019) Netarsudil Increases Outflow Facility in Human Eyes Through Multiple Mechanisms. Invest Ophthalmol Vis Sci 57:6197\u20136209. https:\/\/doi.org\/10.1167\/iovs.16-20189","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"6192_CR21","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1007\/s12325-020-01277-2","volume":"37","author":"S Asrani","year":"2020","unstructured":"Asrani S, Bacharach J, Holland E et al (2020) Fixed-Dose Combination of Netarsudil and Latanoprost in Ocular Hypertension and Open-Angle Glaucoma: Pooled Efficacy\/Safety Analysis of Phase 3 MERCURY-1 and -2. Adv Ther 37:1620\u20131631. https:\/\/doi.org\/10.1007\/s12325-020-01277-2","journal-title":"Adv Ther"},{"key":"6192_CR22","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.ajo.2019.06.016","volume":"207","author":"S Asrani","year":"2019","unstructured":"Asrani S, Robin AL, Serle JB et al (2019) Netarsudil\/Latanoprost Fixed-Dose Combination for Elevated Intraocular Pressure: Three-Month Data from a Randomized Phase 3 Trial. Am J Ophthalmol 207:248\u2013257. https:\/\/doi.org\/10.1016\/j.ajo.2019.06.016","journal-title":"Am J Ophthalmol"},{"key":"6192_CR23","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.ogla.2019.03.007","volume":"2","author":"TR Walters","year":"2019","unstructured":"Walters TR, Ahmed IIK, Lewis RA et al (2019) Once-Daily Netarsudil\/Latanoprost Fixed-Dose Combination for Elevated Intraocular Pressure in the Randomized Phase 3 MERCURY-2 Study. Ophthalmol Glaucoma 2:280\u2013289. https:\/\/doi.org\/10.1016\/j.ogla.2019.03.007","journal-title":"Ophthalmol Glaucoma"},{"key":"6192_CR24","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s00417-022-05780-w","volume":"261","author":"JC Wong","year":"2023","unstructured":"Wong JC, Shiuey EJ, Razeghinejad R et al (2023) The effectiveness and tolerability of fixed-dose combination netarsudil 0.02%\/latanoprost 0.005% at a tertiary glaucoma center. Graefes Arch Clin Exp Ophthalmol 261:193\u2013200. https:\/\/doi.org\/10.1007\/s00417-022-05780-w","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"6192_CR25","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1097\/IJG.0b013e3181507313","volume":"17","author":"JD Brandt","year":"2008","unstructured":"Brandt JD, Cantor LB, Katz LJ et al (2008) Bimatoprost\/timolol fixed combination: a 3-month double-masked, randomized parallel comparison to its individual components in patients with glaucoma or ocular hypertension. J Glaucoma 17:211\u2013216. https:\/\/doi.org\/10.1097\/IJG.0b013e3181507313","journal-title":"J Glaucoma"},{"key":"6192_CR26","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1016\/j.ophtha.2007.10.004","volume":"115","author":"WC Stewart","year":"2008","unstructured":"Stewart WC, Konstas AG, Nelson LA, Kruft B (2008) Meta-analysis of 24-hour intraocular pressure studies evaluating the efficacy of glaucoma medicines. Ophthalmology 115:1117\u20131117-22 e1. https:\/\/doi.org\/10.1016\/j.ophtha.2007.10.004","journal-title":"Ophthalmology"},{"key":"6192_CR27","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.alit.2016.12.004","volume":"66","author":"E Takamura","year":"2017","unstructured":"Takamura E, Uchio E, Ebihara N et al (2017) Japanese guidelines for allergic conjunctival diseases 2017. Allergol Int 66:220\u2013229. https:\/\/doi.org\/10.1016\/j.alit.2016.12.004","journal-title":"Allergol Int"},{"key":"6192_CR28","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1097\/IJG.0000000000001634","volume":"29","author":"IP Singh","year":"2020","unstructured":"Singh IP, Fechtner RD, Myers JS et al (2020) Pooled Efficacy and Safety Profile of Netarsudil Ophthalmic Solution 0.02% in Patients With Open-angle Glaucoma or Ocular Hypertension. J Glaucoma 29:878\u2013884. https:\/\/doi.org\/10.1097\/IJG.0000000000001634","journal-title":"J Glaucoma"},{"key":"6192_CR29","doi-asserted-by":"publisher","unstructured":"Holl\u00f3 G, Whitson JT, Faulkner R et al (2006) Concentrations of betaxolol in ocular tissues of patients with glaucoma and normal monkeys after 1 month of topical ocular administration. Invest Ophthalmol Vis Sci 47:235\u2013240. https:\/\/doi.org\/10.1167\/iovs.05-0945","DOI":"10.1167\/iovs.05-0945"},{"key":"6192_CR30","doi-asserted-by":"publisher","unstructured":"Holl\u00f3 G, Kothy P (2008) Intraocular pressure reduction with travoprost\/timolol fixed combination, with and without adjunctive brinzolamide, in glaucoma. Curr Med Res Opin 24:1755\u20131761. https:\/\/doi.org\/10.1185\/03007990802159273","DOI":"10.1185\/03007990802159273"},{"key":"6192_CR31","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1038\/sj.eye.6701345","volume":"18","author":"AG Konstas","year":"2004","unstructured":"Konstas AG, Mylopoulos N, Karabatsas CH et al (2004) Diurnal intraocular pressure reduction with latanoprost 0.005% compared to timolol maleate 0.5% as monotherapy in subjects with exfoliation glaucoma. Eye (Lond) 18:893\u2013899. https:\/\/doi.org\/10.1038\/sj.eye.6701345","journal-title":"Eye (Lond)"},{"key":"6192_CR32","doi-asserted-by":"publisher","first-page":"2541","DOI":"10.2147\/OPTH.S76053","volume":"8","author":"NM Radcliffe","year":"2014","unstructured":"Radcliffe NM (2014) The impact of timolol maleate on the ocular tolerability of fixed-combination glaucoma therapies. Clin Ophthalmol 8:2541\u20132549. https:\/\/doi.org\/10.2147\/OPTH.S76053","journal-title":"Clin Ophthalmol"},{"key":"6192_CR33","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.survophthal.2016.11.008","volume":"62","author":"MB Raizman","year":"2017","unstructured":"Raizman MB, Hamrah P, Holland EJ et al (2017) Drug-induced corneal epithelial changes. Surv Ophthalmol 62:286\u2013301. https:\/\/doi.org\/10.1016\/j.survophthal.2016.11.008","journal-title":"Surv Ophthalmol"},{"key":"6192_CR34","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1007\/s12325-020-01227-y","volume":"37","author":"CE Wisely","year":"2020","unstructured":"Wisely CE, Sheng H, Heah T, Kim T (2020) Effects of Netarsudil and Latanoprost Alone and in Fixed Combination on Corneal Endothelium and Corneal Thickness: Post-Hoc Analysis of MERCURY-2. Adv Ther 37:1114\u20131123. https:\/\/doi.org\/10.1007\/s12325-020-01227-y","journal-title":"Adv Ther"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-023-06192-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00417-023-06192-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-023-06192-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,23]],"date-time":"2024-01-23T06:12:39Z","timestamp":1705990359000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00417-023-06192-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,24]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["6192"],"URL":"https:\/\/doi.org\/10.1007\/s00417-023-06192-0","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,24]]},"assertion":[{"value":"25 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2023","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"One of the supplementary files is missing which resulted to incorrect linking of the supplementary files. This has been added and the supplementary file captions have been corrected.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Independent Ethics Committee (IEC) or Institutional Review Board (IRB). The clinical study protocol, protocol amendments, materials used to recruit subjects, informed consent forms (ICFs) and materials to document consent, and any other appropriate study-related documents were reviewed and approved by\u00a0IECs and Competent Ethics Committees (CECs) before initiations of the study at each study center.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"This study was conducted in accordance with the accepted version of the Declaration of Helsinki, United States Food and Drug Administration (FDA) Law, the European Union (EU) Clinical Trials Directive 2001\/20\/EC, in compliance with International Council for Harmonization (ICH) good clinical practice (GCP) E6 R2 guidelines, and according to the appropriate regulatory requirements in the countries where the study was conducted.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical conduct of the study"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"IS reports financial support from Aerie Pharmaceuticals Ireland Ltd\u00a0during the conduct of this study; and grants and personal fees from Th\u00e9a and Santen, personal fees from Eye-D Pharma, Allergan-Abbvie, Horus and Alcon, and  is a\u00a0co-founder and\u00a0shareholder of, and consultant\u00a0for, MONA, outside the submitted work.KSL reports grants and lecture fees from Santen during the conduct of the study.FO reports grants and personal fees from Santen and Abbvie outside the submitted work.MF reports personal fees and non-financial support from Santen outside the submitted work.JIB reports personal fees from Glaukos, Zeiss and Santen, and personal fees and non-financial support from Esteve, outside the submitted work.AH reports personal fees from Aerie Pharmaceuticals Ireland Ltd\u00a0during the conduct of this study, and personal fees from Th\u00e9a and Santen outside the submitted work.GL has nothing to disclose.CS reports personal fees from Abbvie, Horus, Glaukos, Th\u00e9a, Alcon, Santen, Nicox and Johnson & Johnson outside the submitted work.BV reports grants from Aerie Pharmaceuticals Ireland Ltd\u00a0during the conduct of this study and grants from Santen outside the submitted work.TZ has nothing to disclose.GH reports personal fees from Santen outside the submitted work.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}